Literature DB >> 31431076

A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.

Kazem Nouri1, Taha Azad1, Elizabeth Lightbody1, Prem Khanal1, Christopher J Nicol1, Xiaolong Yang1.   

Abstract

The Hippo pathway is an emerging signaling pathway that plays important roles in organ size control, tissue homeostasis, tumorigenesis, metastasis, drug resistance, and immune response. Although many regulators of the Hippo pathway have been reported, the extracellular stimuli and kinase regulators of the Hippo pathway remain largely unknown. To identify novel regulars of the Hippo pathway, in this study we created the first ultra-bright NanoLuc biosensor (BS) to monitor the activity of large tumor suppressor (LATS) kinase 1, a central player of the Hippo pathway. We show that this NanoLuc BS achieves significantly advanced sensitivity and stability both in vitro using purified proteins and in vivo in living cells and mice. Using this BS, we perform the first kinome-wide screen and identify many kinases regulating LATS and its effectors yes-associated protein (YAP) and transcriptional co-activator with PDZ- binding motif (TAZ). We also show for the first time that activation of receptor tyrosine kinase anaplastic lymphoma kinase (ALK) by its extracellular ligand family with sequence similarity (FAM)150 activates Hippo effector YAP/TAZ by increasing their nuclear translocation. Significantly, we show that constitutively active ALK induces tumorigenic phenotypes, such as increased cancer cell proliferation/colony formation via YAP/TAZ and elevated immune evasion via YAP/TAZ-programmed death-ligand 1 in breast and lung cancer cells. In summary, we have developed a new LATS BS for cancer biology and therapeutics research and uncovered a novel ALK-LATS-YAP/TAZ signaling axis that may play important roles in cancer and possibly other biologic processes.-Nouri, K., Azad, T., Lightbody, E., Khanal, P., Nicol, C. J., Yang, X. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.

Entities:  

Keywords:  PD-L1; breast cancer; immunotherapy; kinases; lung cancer

Mesh:

Substances:

Year:  2019        PMID: 31431076      PMCID: PMC6902680          DOI: 10.1096/fj.201901343R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  45 in total

Review 1.  The Hippo pathway in organ development, homeostasis, and regeneration.

Authors:  Vivian Fu; Steven W Plouffe; Kun-Liang Guan
Journal:  Curr Opin Cell Biol       Date:  2018-01-06       Impact factor: 8.382

Review 2.  Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives.

Authors:  Zhifa Cao; Qian Gao; Meixian Fu; Nan Ni; Yuting Pei; Wen-Bin Ou
Journal:  Oncol Lett       Date:  2018-12-20       Impact factor: 2.967

Review 3.  Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance.

Authors:  Kalyana C Nandipati; Saravanan Subramanian; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2016-11-21       Impact factor: 3.396

4.  PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways.

Authors:  Tess Montminy; Taha Azad; Elizabeth Lightbody; Yulei Zhao; Yawei Hao; Sandip SenGupta; Eric Asselin; Christopher Nicol; Xiaolong Yang
Journal:  Mol Cancer Res       Date:  2018-03-15       Impact factor: 5.852

Review 5.  The role of the ALK receptor in cancer biology.

Authors:  B Hallberg; R H Palmer
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

6.  Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Authors:  Curtis A Clark; Harshita B Gupta; Gangadhara Sareddy; Srilakshmi Pandeswara; Shunhua Lao; Bin Yuan; Justin M Drerup; Alvaro Padron; José Conejo-Garcia; Kruthi Murthy; Yang Liu; Mary Jo Turk; Kathrin Thedieck; Vincent Hurez; Rong Li; Ratna Vadlamudi; Tyler J Curiel
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

7.  A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.

Authors:  Simona Pavan; Nathalie Meyer-Schaller; Maren Diepenbruck; Ravi Kiran Reddy Kalathur; Meera Saxena; Gerhard Christofori
Journal:  Oncogene       Date:  2018-05-01       Impact factor: 9.867

Review 8.  YAP/TAZ at the Roots of Cancer.

Authors:  Francesca Zanconato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

9.  A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis.

Authors:  T Azad; H J Janse van Rensburg; E D Lightbody; B Neveu; A Champagne; A Ghaffari; V R Kay; Y Hao; H Shen; B Yeung; B A Croy; K L Guan; F Pouliot; J Zhang; C J B Nicol; X Yang
Journal:  Nat Commun       Date:  2018-03-13       Impact factor: 14.919

10.  A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability.

Authors:  Li Wang; Carolyn J Adamski; Vitaliy V Bondar; Evelyn Craigen; John R Collette; Kaifang Pang; Kihoon Han; Antrix Jain; Sung Y Jung; Zhandong Liu; Richard N Sifers; J Lloyd Holder; Huda Y Zoghbi
Journal:  Mol Psychiatry       Date:  2019-01-29       Impact factor: 15.992

View more
  12 in total

1.  Mst1/2-ALK promotes NLRP3 inflammasome activation and cell apoptosis during Listeria monocytogenes infection.

Authors:  Aijiao Gao; Huixin Tang; Qian Zhang; Ruiqing Liu; Lin Wang; Yashan Liu; Zhi Qi; Yanna Shen
Journal:  J Microbiol       Date:  2021-04-20       Impact factor: 3.422

2.  Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors.

Authors:  Kazem Nouri; Taha Azad; Min Ling; Helena J Janse van Rensburg; Alexander Pipchuk; He Shen; Yawei Hao; Jianmin Zhang; Xiaolong Yang
Journal:  Cancers (Basel)       Date:  2019-10-19       Impact factor: 6.639

Review 3.  Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis.

Authors:  Taha Azad; Reza Rezaei; Abera Surendran; Ragunath Singaravelu; Stephen Boulton; Jaahnavi Dave; John C Bell; Carolina S Ilkow
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639

Review 4.  Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review.

Authors:  Gianmarco Leone; Francesco Passiglia; Paolo Bironzo; Valentina Bertaglia; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2020-12

Review 5.  Targeting the Hippo Pathway in Prostate Cancer: What's New?

Authors:  Kelly Coffey
Journal:  Cancers (Basel)       Date:  2021-02-04       Impact factor: 6.575

Review 6.  Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer.

Authors:  Ioanna Mourkioti; Andriani Angelopoulou; Konstantinos Belogiannis; Nefeli Lagopati; Spyridon Potamianos; Efthymios Kyrodimos; Vassilis Gorgoulis; Angelos Papaspyropoulos
Journal:  Cells       Date:  2022-08-07       Impact factor: 7.666

Review 7.  Anaplastic lymphoma kinase-special immunity and immunotherapy.

Authors:  Ye Guo; Hanfei Guo; Yongfei Zhang; Jiuwei Cui
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 8.  Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches.

Authors:  Kamya Sankar; Sunitha Nagrath; Nithya Ramnath
Journal:  Cancers (Basel)       Date:  2021-03-23       Impact factor: 6.639

9.  A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion.

Authors:  Taha Azad; Reza Rezaei; Ragunath Singaravelu; Taylor R Jamieson; Mathieu J F Crupi; Abera Surendran; Joanna Poutou; Parisa Taklifi; Juthaporn Cowan; Donald William Cameron; Carolina S Ilkow
Journal:  Nanomaterials (Basel)       Date:  2021-03-22       Impact factor: 5.076

Review 10.  Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity.

Authors:  Huey-Jen Lin; Yingguang Liu; Denene Lofland; Jiayuh Lin
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.